Top Searches
February 4, 2012
| Bio-IT World > Champions 2.0(2)


Champions 2.0(2)



March 12, 2007 |  Five years ago, the inaugural issue of Bio•IT World featured a series of introductory interviews with the key executives and evangelists of 60 companies, enabling industry legends and rookie entrepreneurs alike to share their views on the bio-IT industry (see Champions of Bio-IT, March 2002). To mark our 5th anniversary, we offer the 2007 remix — Champions 2.0! We invited senior executives from 50 outstanding technology providers to answer a few simple questions. Here was their chance to reflect on their company's survival, their latest technology offerings, and their prospects looking ahead.

On the following pages, we feature the complete set of unedited answers for all our Champions.We use the term "Champions" as much in the sense of "advocate, fighter, and defender" as "winner." And for good reason, since of the companies featured in our first issue, 25 percent (and many more faces) have disappeared or changed. Several others are struggling to overcome ongoing challenges facing platform and tool providers.

A marked change in 2007 is the appearance of a number of eClinical companies, a field Bio•IT World now covers in depth, and key partners in expediting the passage of safe drugs. Microsoft, absent five years ago, not only appears but also is cited by several other executives for the expanding influence of its BioIT Alliance.

A couple of caveats: first and foremost, we do not claim this to be a scientific survey, merely illustrative of companies that are succeeding in their respective sectors, or that appear poised to do so. We should also note that a handful of companies we approached declined to participate, citing time constraints or other factors.

Our thanks to all of the executives for their time and cooperation. We trust we will see them — and you — in five years.

Allison Proffitt
Kevin Davies

Computing / IT Infrastructure

Abrevity — Joel Harrison, CTO

Active Motif — Christopher Hoover, TimeLogic Product Manager; Darryl Leon, AKS Product Manager

Adobe Systems Inc. — Melonie Warfel, Director WW Standards & Life Sciences

Apple Computer — Elizabeth Kerr, Director, Science and Technology Markets, Worldwide Pro Markets

BlueArc Corporation — James Reaney, Director, Research Markets

EMC Corporation — Roberta Katz, Director, Global Solutions Lead, Healthcare-Life Sciences

HP — Harry Kim, Director WW Health and Life Sciences

IBM — Michael Svinte, Vice President, Global Innovation, IBM Healthcare and Life Sciences

Isilon Systems -- Sujal Patel, Founder & CTO

Infosys — Eric Paternoster, Head, Life Sciences Business Unit

Microsoft — Don Rule, Platform Strategy Advisor

Oracle Corporation — Mychelle Mowrey, Vice President for Global Health Industries

Penguin Computing — Pauline Nist, Senior Vice President, Product Development & Management

SGI — Eng Lim Goh, Chief Technology Officer

Sun Microsystems — Joerg Schwarz, Director, Healthcare and Life Sciences

Informatics / Data Management

Accelrys — Mark Emkjer, President and CEO

CambridgeSoft — Michael Tomasic, Chairman, President, and CEO

Elsevier MDL — Lars Barfod, President and CEO

GenoLogics — Michael Ball, CEO

InforSense — Yike Guo, CEO and Founder

LabVantage Solutions — Jim Aurelio, President and CEO

SAS — Ed Helton, Chief Pharmaceutical and Regulatory Scientist

Spotfire — Christopher Ahlberg, Founder and CEO

The MathWorks — Jim Tung, MathWorks Fellow

Symyx — Isy Goldwasser, President

Clinical Trials Technology

ClinPhone — Steve Kent, CEO

Cognos — Bill Stevens, Senior Director, Life Sciences Solutions

Etrials Worldwide — John Cline, CEO

Nextrials — James Rogers, President and CEO

Phase Forward — Bob Weiler, President and CEO

Phoenix Data Systems — Bill Claypool, CEO

Knowledge Mining

Entelos — James Karis, President and CEO

Genstruct — Keith Elliston, President and CEO

Ingenuity — Jake Leschly, President and CEO; Ramon Feliciano, CTO and Vice President of Research

Insightful — Michael O’Connell, Director of Life Science Solutions

Pharsight — Shawn O’Connor, President and CEO

GNS — Colin Hill, CEO and Co-founder

GeneGo — Tatiana Nikolskaya, President and Founder, CSO

Linguamatics — Roger Hale, COO

Genomics / Proteomics

454 Life Sciences — Christopher McLeod, President and CEO

Agilent Technologies — Chris van Ingen, Senior Vice President

Applied Biosystems — Dennis Gilbert, Chief Scientific Officer

Caliper Life Sciences — Kevin Hrusovsky, President and CEO

Illumina — Jay Flatley, President and CEO

Thermo Fisher Scientific — Marc Casper, Executive Vice President

Bruker Daltonics — Herbert Thiele, Worldwide Head of Bioinformatics

Geospiza — Rob Arnold, President

Teranode — Joseph Duncan, CEO

Nanosphere — William Moffitt, President and CEO

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 

COMPLIMENTARY DOWNLOAD


accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 
DOWNLOAD SURVEY NOW
More White Papers & Special Reports
Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 






For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com . 

Cambridge Healthtech Institute

Footer Image
  • 250 First Avenue, Suite 300
  • Needham MA 02494
  • phone: 781-972-5400
  • fax: 781-972-5425
  • chi@healthtech.com